Safety analysis of RCTs showed Alzheimer’s drug Aducanumab caused brain swelling in 35% of patients, and 26.0% experienced associated symptoms (e.g., headache, confusion, dizziness, and nausea).

Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease – JAMA Neurology

Commentary: Biogen Alzheimer’s drug shows brain swelling in 35% of patients – MedicalXpress

Commentary on Twitter

Amyloid-related imaging abnormalities occurred in ~ 40% of participants in the phase 3 studies of aducanumab. Approximately one-quarter of patients with amyloid-related imaging abnormalities experience symptoms https://t.co/TnUPXT686l

— JAMA Neurology (@JAMANeuro) November 22, 2021